Renovaro Management
Management criteria checks 3/4
Renovaro's CEO is Mark Dybul, appointed in Jul 2021, has a tenure of 2.83 years. total yearly compensation is $1.41M, comprised of 47.3% salary and 52.7% bonuses, including company stock and options. directly owns 0.046% of the company’s shares, worth $105.03K. The average tenure of the management team and the board of directors is 1.8 years and 4.4 years respectively.
Key information
Mark Dybul
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 47.3% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.05% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Enochian stock climbs on US patent for oncology platform
Oct 17Enochian BioSciences discovers two sets of altered animal data in two of its studies
Jul 01Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?
Jun 28
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Feb 20Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Oct 30Enochian Biosciences: A Follow Through For An HIV Cure
Jun 26Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment
Jun 14Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?
Feb 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | US$1m | US$665k | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$107m |
| Dec 31 2022 | n/a | n/a | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$111m |
| Jun 30 2022 | US$11m | US$850k | -US$113m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | n/a | n/a | -US$38m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | US$430k | US$430k | -US$27m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | n/a | n/a | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$10m |
| Jun 30 2020 | US$1m | US$430k | -US$11m |
| Mar 31 2020 | n/a | n/a | -US$6m |
| Dec 31 2019 | n/a | n/a | -US$7m |
| Sep 30 2019 | n/a | n/a | -US$22m |
| Jun 30 2019 | US$2m | US$210k | -US$18m |
| Mar 31 2019 | n/a | n/a | -US$21m |
| Dec 31 2018 | n/a | n/a | -US$21m |
| Sep 30 2018 | n/a | n/a | -US$6m |
| Jun 30 2018 | US$76k | n/a | -US$6m |
Compensation vs Market: Mark's total compensation ($USD1.41M) is about average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Dybul (59 yo)
2.8yrs
Tenure
US$1,405,433
Compensation
Honorable Dr. Mark R. Dybul, M.D., serves as Chief Executive Officer at Enochian Biosciences, Inc. since July 1, 2021. He served as Executive Vice-Chair of Renovaro Biosciences Inc. (formerly known as Enoc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Director & Member of HBV Scientific Advisory Board | 2.8yrs | US$1.41m | 0.046% $ 105.0k | |
| COO and Executive VP for Research & Development | 1.5yrs | US$881.57k | 0% $ 0 | |
| Co-Founder & Inventor | no data | no data | 8.66% $ 19.7m | |
| Interim Chief Financial Officer | less than a year | no data | no data | |
| Senior Vice President for Clinical Operations | 2.1yrs | no data | no data |
1.8yrs
Average Tenure
59yo
Average Age
Experienced Management: RENB's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Director & Member of HBV Scientific Advisory Board | 6.3yrs | US$1.41m | 0.046% $ 105.0k | |
| Member of HBV Scientific Advisory Board | 2.8yrs | no data | no data | |
| Lead Independent Board Member | 4.4yrs | US$133.21k | 0% $ 0 | |
| Independent Director | 6.2yrs | US$133.62k | 0% $ 0 | |
| Chairperson of HBV Cure Scientific Advisory Board & Independent Director | 4.4yrs | US$124.71k | 0% $ 0 | |
| Member of HBV Scientific Advisory Board | 3.8yrs | no data | no data | |
| Independent Director | 3yrs | US$131.25k | 0% $ 0 | |
| Chairman of the Board | 6.9yrs | US$153.71k | 0% $ 0 | |
| Chairman of HIV Scientific Advisory Board | 5.8yrs | no data | no data | |
| Member of HIV Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of HBV Scientific Advisory Board | 3.8yrs | no data | no data | |
| Chairman of Scientific Advisory Board | less than a year | no data | no data |
4.4yrs
Average Tenure
60yo
Average Age
Experienced Board: RENB's board of directors are considered experienced (4.4 years average tenure).